Supplementary material is available online at
Neuro-Oncology (http://neuro-oncology.oxfordjournals.
org/).
Conflict of interest statement. None declared.
Funding
This work was supported by grants from Taichung Veterans General Hospital Clinical Research
(101DHA0500377); the Department of Health, Executive Yuan, Taipei, Taiwan, to the China Medical University Hospital, Cancer Research of Excellence program (DOH101-TD-C-111–005); and the National Science Council (NSC 101-2320-B-005-002).
References
1. Stupp R, Hegi ME, MasonWP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in
glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10:459–466.
2. Andreana LR, Christopher EP,Mark R, et al.MGMTpromotermethylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma. Neuro Oncol.
2010;12:116–121.
3. Nobusawa S,Watanabe T, Kleihues P, Ohgaki H. IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. Clin
Cancer Res. 2009;15:6002–6007.
4. Labussie` re M, Idbaih A, Wang XW, et al. All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2. Neurology. 2010;74(23):
1886–1890.
5. Kaneshiro D, Kobayashi T, Chao ST, Suh J, Prayson RA. Chromosome 1p and 19q deletions in glioblastoma multiforme. Appl Immunohistochem
Mol Morphol. 2009;17(6):512–516.
6. Squatrito M, BrennanCW, Helmy K, Huse JT, Petrini JH, Holland EC. Loss of ATM/Chk2/p53 pathway components accelerates tumor development and contributes to radiation resistance in gliomas. Cancer Cell.
2010;18(6):619–629.
Fig. 5. Type of cell death after irradiation in T98G/ATAD3Akd cells. (A)ATAD3Akd increased autophagy-like vacuoles (black arrows), as shownin
transmission electronmicrographs. (B) Decreased nuclearATMand a noticeableamountof cytoplasmicATMwere observed inT98G/ATAD3Akd
cells after irradiation by confocal immunofluorescent micrographs. (C) Immunoblotting confirmed attenuated ATM in T98G/ATAD3Akd cells
after irradiation. (D) Irradiation did not increase apoptotic cell death as assessed by sub-G1 population in T98G/ATAD3Akd cells. (E) No
difference of cleaved PARP but markedly activated PARP-1 before and after irradiation was noted in T98G/ATAD3Akd cells. Instead,
conversion of LC3-I to LC3-II was evident after irradiation. LC3-II/LC3-I ratio was normalized with corresponding b-actin level.
You et al.: ATAD3A is a radioresistant marker in GBM
NEURO-ONCOLOGY † OCTOB E R 2 0 1 3 1351
Downloaded from http://neuro-oncology.oxfordjournals.org/ at China Medical University Library on March 24, 2014 7. Roy K,Wang L, MakrigiorgosGM,Price BD. Methylation of theATMpromoter
in glioma cells alters ionizing radiation sensitivity. BiochemBiophys Res Commun. 2006;344(3):821–826.
8. Tribius S, Pidel A, Casper D. ATMprotein expression correlates with radioresistance in primary glioblastoma cells in culture. Int J Radiat Oncol Biol
Phys. 2001;50(2):511–523.
9. Choi S,GamperAM,White JS, Bakkenist CJ. Inhibition ofATMkinase activity does not phenocopy ATMprotein disruption: implications for the clinical utility of ATM kinase inhibitors. Cell Cycle. 2010;9(20):4052–4057.
10. Valentin-Vega YA, Maclean KH, Tait-Mulder J, et al. Mitochondrial dysfunction
in ataxia-telangiectasia. Blood. 2012;119(6):1490–1500.
11. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation.
Science. 2009;324:1029–1033.
12. Modica-Napolitano JS, Kulawiec M, Singh KK. Mitochondria and human cancer. Curr Mol Med. 2007;7:121–131.
13. Dmitrenko V, Shostak K, Boyko O, et al. Reduction of the transcription level of the mitochondrial genome in human glioblastoma. Cancer Lett.
2005;218:99–107.
14. Kirches E, Krause G,Warich-KirchesM,et al. High frequency ofmitochondrial DNA mutations in glioblastoma multiforme identified by direct sequence.
Int J Cancer. 2001;93(4):534–538.
15. de Moura MB, dos Santos LS, Van HB. Mitochondrial dysfunction in neurodegenerative diseases. Environ Mol Mutagen. 2010;51(5):391–405.
16. Griguer CE, Oliva CR. Bioenergetics pathways and therapeutic resistance in gliomas: emerging role of mitochondria. Curr Pharm Des.
2011;17(23):2421–2427.
17. Gilquin B, Cannon BR, Hubstenberger A, et al. The calcium-dependent interaction between S100B and the mitochondrial AAA ATPase ATAD3A
and the role of this complex in the cytoplasmic processing of ATAD3A.
Mol Cell Biol. 2010;30:2724–2736.
18. Chiang SF, Huang CY, Lin TY, Chiou SH, Chow KC. An alternative import
pathway of AIF to the mitochondria. Int J Mol Med. 2012;29:365–372.
19. FangHY, Chang CL, Hsu SH, et al. ATPase family AAAdomain-containing 3A is a novel anti-apoptotic factor in lung adenocarcinoma cells. J Cell Sci.
2010;123:1171–1180.
20. Geuijen CA, Bijl N, Smit RC, et al. A proteomic approach to tumour target identification using phage display, affinity purification and mass. Eur J Cancer 2005;41:178–187.
21. Gires O, Munz M, Schaffrik M, et al. Profile identification of
disease-associated humoral antigens using AMIDA, a novel proteomicsbased technology. Cell Mol Life Sci. 2004;61:1198–1207.
22. ChenTC,HungYC,LinTY, et al.Humanpapillomavirus infectionandexpression of ATPase family AAA domain containing 3A, a novel anti-autophagy
factor, in uterine cervical cancer. Int JMolMed. 2011;28:689–696.
23. Huang KH, Chow KC, Chang HW, Lin TY, Lee MC. ATPase family AAA domain containing 3A is an anti-apoptotic factor and a secretion regulator of PSA in prostate cancer. Int J Mol Med. 2011;28:9–15.
24. Hubstenberger A, Labourdette G, Baudier J, Rousseau D. ATAD 3A and ATAD 3B are distal 1p-located genes differentially expressed in human
glioma cell lines and present in vitro anti-oncogenic and chemoresistant properties. Exp Cell Res. 2008;314:2870–2883.
25. Smith JS, Alderete B, Minn Y, et al. Localization of common deletion regions on 1p and 19q in human glioma and their association with histological subtype. Oncogene. 1999;18(28):4144–4152.
26. Stupp R, Hegi ME, van den Bent MJ, et al. Changing paradigms—an update on the multidisciplinary management of malignant glioma.
Oncologist. 2006;11(2):165–180.
27. RemmeleW, Schicketanz KH. Immunohistochemical determination of estrogen and progesterone receptor content in human breast cancer.
Computer-assisted image analysis (QIC score) vs. subjective grading (IRS). Pathol Res Pract. 1993;189:862–866.
28. Challberg MD, Kelly TJ, Jr. AdenovirusDNA replication in vitro: origin and direction of daughter strand synthesis. J Mol Biol. 1979;135(4):
999–1012.
29. Ambrose M, Goldstine JV, Gatti RA. Intrinsic mitochondrial dysfunction in ATM-deficient lymphoblastoid cells. Hum Mol Genet. 2007;16(18):
2154–2164.
30. Tentori L, Portarena I, Torino F, Scerrati M, Navarra P, Graziani G.
Poly(ADP-ribose) polymerase inhibitor increases growth inhibition and reduces G(2)/Mcell accumulation induced bytemozolomide in malignant glioma cells. Glia. 2002;40:44–54.
31. Oliva CR, Nozell SE, Diers A, et al. Acquisition of temozolomide chemoresistance in gliomas leads to remodeling ofmitochondrial electron transport
chain. J Biol Chem. 2010;285:39759–39767.
32. Le Calve´ B, Rynkowski M, Le Mercier M, et al. Long-term in vitro
treatment of human glioblastoma cells with temozolomide increases resistance in vivo through up-regulation of GLUT transporter and aldoketo reductase enzyme AKR1C expression. Neoplasia. 2010;12:
727–739.
33. Chen J, Emara N, Solomides C, Parekh H, Simpkins H. Resistance to platinum-based chemotherapy in lung cancer cell lines. Cancer Chemother Pharmacol. 2010;66(6):1103–1111.
34. Deng HB, Parekh HK,ChowKC, Simpkins H. Increased expression of dihydrodiol
dehydrogenase induces resistance to cisplatin in human ovarian carcinoma cells. J Biol Chem. 2002;277:15035–15043.
35. Hung JJ, Chow KC,WangHW,Wang LS. Expression of dihydrodiol dehydrogenase and resistance to chemotherapyand radiotherapy in adenocarcinoma
cells of lung. Anticancer Res. 2006;26:2949–2955.
36. Eaton JS, Lin ZP, Sartorelli AC, Bonawitz ND, Shadel GS.
Ataxia-telangiectasia mutated kinase regulates ribonucleotide reductase and mitochondrial homeostasis. J Clin Invest. 2007;117(9):2723–2734.
37. Watters D,KedarP, Spring K, et al. Localization of a portion of extranuclear ATM to peroxisomes. J Biol Chem. 1999;274(48):34277–34282.
38. Li J, Han YR, Plummer MR, Herrup K. Cytoplasmic ATM in neurons modulates synaptic function. Curr Biol. 2009;19(24):2091–2096.
39. Cascone A, Bruelle C, Lindholm D, Bernardi P, Eriksson O. Destabilization of the outer and inner mitochondrial membranes by core and linker histones.
PLoS One. 2012;7(4):e35357.
40. Rone MB, Midzak AS, Issop L, et al. Identification of a dynamic mitochondrial protein complex driving cholesterol import, trafficking, and metabolism to steroid hormones. Mol Endocrinol. 2012;26(11):1868–1882.
41. Meador JA, Zhao M, Su Y, Narayan G, Geard CR, Balajee AS. Histone H2AX is a critical factor for cellular protection against DNA alkylating agents. Oncogene. 2008;27(43):5662–5671.
42. Rabinowitz JD, White E. Autophagy and metabolism. Science.
2010;330:1344–1348.
43. Ha HC, Snyder SH. Poly(ADP-ribose) polymerase is a mediator of necrotic cell death by ATP depletion. Proc Natl Acad Sci U S A.
1999;96(24):13978–13982.
You et al.: ATAD3A is a radioresistant marker in GBM
1352 NEURO-ONCOLOGY † OCTOB E R 2 0 1 3
Downloaded from http://neuro-oncology.oxfordjournals.org/ at China Medical University Library on March 24, 2014